When should systemic biologic therapy for psoriasis be discontinued?

When should systemic biologic therapy for psoriasis be discontinued?

Bibliographic Details
Main Authors:	Diem-Phuong D. Dao, Jessica N. Pixley, Steven R. Feldman
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2023-01-01
Series:	Journal of Dermatological Treatment
Online Access:	http://dx.doi.org/10.1080/09546634.2023.2173516

Similar Items

Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?
by: Joeseph Nenow, et al.
Published: (2021-11-01)

Should the presence of psoriatic arthritis change how we manage psoriasis?
by: Warren H. Chan, et al.
Published: (2021-11-01)

Choice Overload in Systemic Psoriasis Therapy
by: Patrick A. Whitman, et al.
Published: (2019-02-01)

Could red and near-infrared emitting fabric technology improve the severity of psoriasis, polymorphous light eruption, and alopecia areata?
by: Jessica N. Pixley, et al.
Published: (2023-12-01)

Medication therapy management in dermatology: a call to action
by: Amaris N. Geisler, et al.
Published: (2021-05-01)

Management of Pediatric Psoriasis: A U.S. Survey Based on Visits from the National Ambulatory Medical Care Survey (NAMCS)
by: Rachel E. Tao, et al.
Published: (2023-10-01)

The onset of psoriasis during the treatment of inflammatory bowel diseases with infliximab: should biological therapy be suspended?
by: Rafael Denadai, et al.
Published: (2012-06-01)

Predicting discontinuation of biologic therapy caused by adverse events in psoriasis patients—A Danish nationwide cohort study
by: Mia‐Louise Nielsen, et al.
Published: (2023-12-01)

Erythrodermic psoriasis after discontinuation of ixekizumab
by: Kathryn Anne Potter, MD, et al.
Published: (2018-01-01)

SHOULD STATINS BE DISCONTINUED IN PERI-OPERATIVE PERIOD?
by: V. V. Lomivorotov, et al.
Published: (2018-08-01)

Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?
by: Luca Mastorino, et al.
Published: (2022-07-01)

Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis
by: Abigail Cline, et al.
Published: (2019-09-01)

When should children with HIV infection be started on antiretroviral therapy?
by: Steven B Welch, et al.
Published: (2008-03-01)

Evolution in psoriasis management
by: Steven R. Feldman
Published: (2017-04-01)

Biological therapies in psoriasis - revisited
by: Sârbu Maria-Isabela, et al.
Published: (2018-06-01)

Should patients stop their biologic treatment during the COVID-19 pandemic
by: Arjun M. Bashyam, et al.
Published: (2020-05-01)

Does hospitalization, independent of other treatment, improve severe chronic skin conditions?
by: Diem-Phuong D. Dao, et al.
Published: (2023-01-01)

Rethinking the costs of psoriasis management
by: Steven R. Feldman
Published: (2017-10-01)

Should Mammography Be a Prerequisite Prior to Initiation of Biological Agents in Patients With Psoriasis?
by: Funda Tamer, et al.
Published: (2022-05-01)

Differential access to psoriasis biologic information in English and Spanish
by: Max Oscherwitz, BS, et al.
Published: (2024-06-01)

Demographics and the perception of psoriasis therapy adverse effects and treatment preference: A cross-sectional survey of a convenience sample of people with psoriasis
by: Jeremy K. Bray, BA, et al.
Published: (2020-07-01)

Pharmacogenetics Update on Biologic Therapy in Psoriasis
by: Ester Muñoz-Aceituno, et al.
Published: (2020-12-01)

Old and New Biological Therapies for Psoriasis
by: Kirsten Rønholt, et al.
Published: (2017-11-01)

Impact of Season and Other Factors on Initiation, Discontinuation, and Switching of Systemic Drug Therapy in Patients with Psoriasis: A Retrospective Study
by: Huifang Liang, et al.
Published: (2023-03-01)

Early predictors of efficacy of biological therapy for psoriasis in children
by: D. G. Kuptsova, et al.
Published: (2023-04-01)

When to discontinue treatment of prolactinoma?
by: Wass, J
Published: (2006)

Adverse reactions of biological therapies in patients with psoriasis
by: Maria I. Sârbu, et al.
Published: (2017-04-01)

BCLC-B hepatocellular carcinoma treatment or when should the systemic therapy be started
by: V. V. Breder, et al.
Published: (2018-07-01)

Biological Therapy Survivability in Children with Psoriasis: Cohort Study
by: Roman A. Ivanov, et al.
Published: (2021-11-01)

Systemic Psoriasis Treatment at an Early Age (Part II): Issues of Biological Therapy
by: L. S. Namazova-Baranova, et al.
Published: (2018-02-01)

Psoriasis in areas difficult to treat and biological therapy
by: Anna Lis-Święty, et al.
Published: (2021-08-01)

Chinese Experts Consensus on Biologic Therapy for Psoriasis#
by: Chinese Society of Dermatology, China Dermatologist Association, Dermatology and Venereology Specialized Committee of Chinese Association of Integrative Medicine, et al.
Published: (2020-06-01)

A Case of Paradoxical Reactions to Biologic Therapy for Psoriasis
by: Zhou Q, et al.
Published: (2023-06-01)

Refractory Pediatric Psoriasis and Atopic Dermatitis: The Importance of Therapeutical Adherence and Biological Management
by: Katherine A. Kelly, et al.
Published: (2021-08-01)

Implications of treatment resistant severe psoriasis for benchmarking quality of care
by: Steven R. Feldman
Published: (2017-08-01)

Tratamiento biológico en psoriasis: Revisión bibliográfica Biologic therapy of psoriasis: Literature review
by: MS Lorenzetti, et al.
Published: (2012-06-01)

Topical and Oral Therapies for Childhood Atopic Dermatitis and Plaque Psoriasis
by: Travis Frantz, et al.
Published: (2019-11-01)

Kasr AL-Ainy’s psoriasis unit protocol for the treatment of psoriasis, part II: biological therapies
by: Hoda Rasheed, et al.
Published: (2019-01-01)

Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies
by: Mitchell S. Davis, et al.
Published: (2023-12-01)

Clinical evidence of therapy for genital psoriasis by biologic agents
by: Evgeny V. Sokolovskiy, et al.
Published: (2021-04-01)